Parabilis Soared Biggest Biotech: Is It Too Late to Buy?
A record biotech IPO backdrop has investors buzzing about Parabilis Medicines. This guide breaks down what the surge ...
Identify the major factors influencing funding timing and practical steps to optimize speed from approval to disbursement.
16,493 articlesA record biotech IPO backdrop has investors buzzing about Parabilis Medicines. This guide breaks down what the surge ...
Salesforce plans up to $25 billion in debt to fund an accelerated share repurchase that would buy back roughly 14% of...
Oracle stock faces a pivotal moment as management doubles down on AI infrastructure while financing plans raise dilut...
In the fast-moving world of micro-scale tech, rapid micro (rpid) earnings calls can signal whether a company is susta...
A retired couple weighs whether they can sustain annual trips to Japan to visit family and a yearly volunteering trip...
Capricor's small-cap biotech story hinges on milestones, cash runway, and clinical progress. This guide breaks down w...
A 2026 Trustees Report warns of a roughly 22% cut to Social Security benefits by late 2032 unless policy changes occu...
Investors debate timing as IREN plans a bold AI expansion after a major capital raise. This guide breaks down the pla...
OpenAI's planned IPO faces a timing change that could redefine AI stock bets. The shift underscores a tougher funding...
Robinhood just announced a substantial $1.5 billion buyback. In this analysis, we weigh the potential benefits agains...
New projections warn the Social Security trust fund could exhaust by 2032, risking benefit cuts unless Congress acts....
Immersed, a private VR work platform behind the work-from-VR trend, is closing its under-$1 retail round. Early metri...